Media Articles Related to Psoriatec (Anthralin)
Psoriasis PUVA Therapy Can Increase Melanoma Risk
Source: MedicineNet Cancer Specialty [2017.01.20]
Title: Psoriasis PUVA Therapy Can Increase Melanoma Risk
Category: Doctor's & Expert's views on Symptoms
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/20/2017 12:00:00 AM
Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis
Source: Medscape Allergy & Clinical Immunology Headlines [2017.01.17]
Guselkumab is effective for treating patients with moderate to severe psoriasis, according to results from Janssen's VOYAGE 1 and VOYAGE 2 trials.
Reuters Health Information
Genital Psoriasis: Symptoms and Treatment
Source: Sexual Health / STDs News From Medical News Today [2017.01.15]
Learn all about genital psoriasis. This article looks at the symptoms and treatments for this condition, as well as how it might affect sexual health.
Weight Loss May Ease Psoriasis Symptoms, Study Finds
Source: MedicineNet Allergy Specialty [2017.01.05]
Title: Weight Loss May Ease Psoriasis Symptoms, Study Finds
Category: Health News
Created: 1/4/2017 12:00:00 AM
Last Editorial Review: 1/5/2017 12:00:00 AM
Health Tip: Caring for Psoriasis on Your Feet
Source: MedicineNet Psoriasis Specialty [2017.01.04]
Title: Health Tip: Caring for Psoriasis on Your Feet
Category: Health News
Created: 1/4/2017 12:00:00 AM
Last Editorial Review: 1/4/2017 12:00:00 AM
Published Studies Related to Psoriatec (Anthralin)
Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. 
CONCLUSION: The present pilot study showed that the use of azelaic acid gave similar results to anthralin with regard to hair regrowth, and that it can be an effective topical therapy for patchy AA. More extensive trials are necessary, however, to reach a definitive conclusion.
Effect of H1-receptor blockade on anthralin inflammation. 
The effect of terfenadine, an H1-receptor antagonist, on anthralin inflammation was studied in 12 subjects. Subjects were randomised to receive terfenadine 60 mg or placebo b.d... This study shows that H1-receptor blockade does not inhibit anthralin inflammation.
Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis. [1988.04]
A prospective randomized trial of anthralin in Lassar's paste compared with anthralin in 0.0125% clobetasol propionate in the treatment of chronic plaque psoriasis was undertaken. The psoriatic skin of patients treated with the corticosteroid-anthralin combination cleared significantly more quickly than those treated with anthralin alone, with a mean time to clearance of 14.9 days compared with 18.5 days, and with lower concentrations of anthralin...
An EPR method for estimating activity of antioxidants in mouse skin using an anthralin-derived radical model. [2010.03]
Inhibitory effects of intravenously or orally administered antioxidants on the anthralin-derived radical generated in skin (mainly in the epidermis) of living mice by ultraviolet-A (UVA) irradiation were estimated. Anthralin was applied to the dorsal skin of living mice and the mice were then exposed to UVA.
Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy. [2009.12]
BACKGROUND: Psoriatic lesions are characterized by induration, scaling and erythema. Erythema is a result of inflammation and increased microvascular blood flow. Anthralin is the strongest topical antipsoriatic drug that causes clearing of psoriatic lesions and temporary remission. OBJECTIVE: The objective evaluation of skin perfusion might be a suitable way to gain a better insight in the pathophysiological process of this disease and to evaluate the response to antipsoriatic anthralin therapy... CONCLUSIONS: Vascular perfusion is increased in psoriatic lesions as demonstrated by remission spectroscopy. NADH-fluorescence is reduced in lesional psoriatic skin and in anthralin-induced erythema. FRIS is a suitable tool for objective evaluation of the cutaneous response to antipsoriatic treatment.
Clinical Trials Related to Psoriatec (Anthralin)
Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis [Recruiting]
(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
loss of PASI (Psoriasis Area and Severity Index) improvement obtained through the antecedent
(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).
- Trial with medicinal product
A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis [Recruiting]
Psoriasis is a distressing, chronic dermatitis. Plague-type psoriasis is the most common
form of the disease, occurring in more than 80% of the cases. This type of psoriasis is
characterised by sharply dermatcated, erythematous, scaling plagues that typically affect
the elbows, knees, scalp, and intergluteal cleft. Estimates of the prevalence of psoriasis
is vary from 0. 5% to 4. 6%, with rate varying between countries and races. The prevalence of
psoriasis was about 2% in Taiwan. The cause of psoriasis remains unknown; however, it has
been linked to complex interactions between predisposing genes and the environment. Current
treatment of psoriasis included topical therapy (eg. topical corticosteroids, tars,
anthralin, vitamin D analogues, Retinodes), phototherapy and systemic therapy (eg.
Methotrexate, cyclosporine, Retinoids, Biologics). Although beneficial, all have undesirable
Evaluation of Vitamin D Levels in Psoriasis Patients [Recruiting]
The purpose of this research study is to find out more about the relationship between
vitamin D and psoriasis.
Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis [Completed]
This study is to determine the effect of adalimumab on inflammation of blood vessels that
could lead to heart attack in patients with psoriasis. Changes to the carotid artery and
ascending aorta will be evaluated in patients treated with adalimumab (systemic treatment)
and compared against patients treated with a topical treatment that does not affect the